PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction [Kansas City]
November 12, 2019
200 E 25th St #400
Kansas City, MO 64108
Tuesday, November 12, 2019
6:30 - 7:00 pm - Registration & Dinner
7:00 - 9:00 pm - Program
This symposium reviews current cardiovascular outcomes data for PCSK9 inhibitors, how to integrate non-statin lipid-lowering therapies and current cholesterol guidelines for the management of high CV-risk patients, and strategies for gaining access to PCSK9 inhibitors for high CV risk patients that need them.
In addition, attendees will have an opportunity to develop a treatment plan for real-world patients and compare and discuss their strategies with the faculty panel. Attendees are also encouraged to bring or submit difficult cases and questions to challenge the faculty in the “Stump the Faculty” segment.
This CME initiative will target Lipid Specialists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), nurse practitioners (NPs), physician assistants (PAs), and other healthcare providers who practice in a primary care setting.
- Assess current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events
- Integrate PCSK9 inhibitors in the management of real-world patients at high CV risk requiring additional LDL-C reduction
- Formulate strategies to improve patient access to PCSK9 inhibitors for those who require further CV risk reduction
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration.
Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.